These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 26697892)
1. Compounded Formulations of Dimethyl Fumarate Show Significant Variability in Product Characteristics. Boulas P Drug Res (Stuttg); 2016 May; 66(5):275-8. PubMed ID: 26697892 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera Lategan TW; Wang L; Sprague TN; Rousseau FS CNS Drugs; 2021 May; 35(5):567-574. PubMed ID: 33797063 [TBL] [Abstract][Full Text] [Related]
3. The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis. Wicks P; Rasouliyan L; Katic B; Nafees B; Flood E; Sasané R BMC Res Notes; 2016 Sep; 9(1):434. PubMed ID: 27604188 [TBL] [Abstract][Full Text] [Related]
4. Accuracy and precision of compounded ciclosporin capsules and solution. Umstead ME; Boothe DM; Cruz-Espindola C; Macdonald JM; Kennis R; Angarano D Vet Dermatol; 2012 Oct; 23(5):431-e82. PubMed ID: 22970897 [TBL] [Abstract][Full Text] [Related]
5. Challenge of paediatric compounding to solid dosage forms sachets and hard capsules - Finnish perspective. Sivén M; Kovanen S; Siirola O; Hepojoki T; Isokirmo S; Laihanen N; Eränen T; Pellinen J; Juppo AM J Pharm Pharmacol; 2017 May; 69(5):593-602. PubMed ID: 27704551 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273 [TBL] [Abstract][Full Text] [Related]
8. Quality of compounded topical 2% diltiazem hydrochloride formulations for anal fissure. Shah M; Sandler L; Rai V; Sharma C; Raghavan L World J Gastroenterol; 2013 Sep; 19(34):5645-50. PubMed ID: 24039356 [TBL] [Abstract][Full Text] [Related]
9. Accuracy of testosterone concentrations in compounded testosterone products. Grober ED; Garbens A; Božović A; Kulasingam V; Fanipour M; Diamandis EP J Sex Med; 2015 Jun; 12(6):1381-8. PubMed ID: 25963000 [TBL] [Abstract][Full Text] [Related]
10. Enhanced Brain Delivery of Dimethyl Fumarate Employing Tocopherol-Acetate-Based Nanolipidic Carriers: Evidence from Pharmacokinetic, Biodistribution, and Cellular Uptake Studies. Kumar P; Sharma G; Kumar R; Malik R; Singh B; Katare OP; Raza K ACS Chem Neurosci; 2017 Apr; 8(4):860-865. PubMed ID: 27983793 [TBL] [Abstract][Full Text] [Related]
11. Analysis of lomustine drug content in FDA-approved and compounded lomustine capsules. KuKanich B; Warner M; Hahn K J Am Vet Med Assoc; 2017 Feb; 250(3):322-326. PubMed ID: 28117638 [TBL] [Abstract][Full Text] [Related]
12. Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. Green DM; Jones AC; Brain KR J Clin Pharm Ther; 2012 Feb; 37(1):53-7. PubMed ID: 21501202 [TBL] [Abstract][Full Text] [Related]
13. Vitamin-Derived Nanolipoidal Carriers for Brain Delivery of Dimethyl Fumarate: A Novel Approach with Preclinical Evidence. Kumar P; Sharma G; Kumar R; Malik R; Singh B; Katare OP; Raza K ACS Chem Neurosci; 2017 Jun; 8(6):1390-1396. PubMed ID: 28157295 [TBL] [Abstract][Full Text] [Related]
14. Assessment of the quality of simvastatin capsules from compounding pharmacies. Markman BE; Rosa PC; Koschtschak MR Rev Saude Publica; 2010 Dec; 44(6):1055-62. PubMed ID: 21107503 [TBL] [Abstract][Full Text] [Related]
15. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada. Dorman E; Kansal AR; Sarda S J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149 [TBL] [Abstract][Full Text] [Related]